Skip to main content
. 2021 Mar 14;11(3):515. doi: 10.3390/diagnostics11030515
68Ga-PSMA-11 PET/CT Gallium-68-PSMA-11 positron emission tomography/computed tomography
177Lu Lutetium-177
177Lu-PSMA I&T 177Lu-DOTAGA-(I-y)fk(Sub-KuE)
ADT Androgen deprivation therapy
AL Acute leukaemia
EANM European Association of Nuclear Medicine
EAU European Association of Urology
EBRT External beam radiotherapy
ECOG European Cooperative Oncology Group
IRB institutional review board
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
mCRPC Metastatic castrate resistant prostate cancer
MDS Myelodysplastic syndrome
OS Overall survival
OR odds ratio
PERCIST PET response criteria in solid tumors
PET/CT Gallium-68-PSMA-11 positron emission tomography/computed tomography
PCWG Prostate Cancer Working Group
PFS Progression-free survival
PSA Prostate-specific antigen
PSMA Prostate-specific membrane antigen
RLT Radioligand therapy